Draft monograph: semaglutide, version 3 — submissions

A near-isobaric analogue is not distinguished by the identity determination described

The respondent read the draft on Semaglutide alongside the approved labelling for the class, and submits on one matter arising.

The identity determination described in the draft resolves the compound from unrelated substances but would not distinguish it from a closely related analogue whose mass differs by approximately one dalton.

The respondent proposes that the monograph state the resolution required for that discrimination, and state that a nominal-mass instrument reporting an integer mass has not made it.

Local reactions are omitted from the adverse-event table because the trials reported them separately

This is a submission on the draft covering Semaglutide, from a respondent whose work is with the people taking compounds of this class rather than with the trials that produced them.

Injection-site reactions are reported in the source trials in a table of their own and do not appear in the systemic adverse-event table the monograph reproduces. The result is that the most common adverse experience of a subcutaneously administered compound is absent from the monograph’s adverse-event section.

The respondent proposes that local reactions be carried in the same table as systemic events, with the reporting convention of the source trial recorded in a footnote.

Glycaemic trials and weight-management trials are drawn on interchangeably

The respondent has read the draft monograph on Semaglutide against a caseload in which incretin analogues are prescribed daily.

The compound has two trial programmes with different populations, different doses and different endpoints. The monograph draws on both without saying which programme a given estimate came from, so a reader takes a weight figure obtained at one dose in one population as though it applied at the other.

The respondent proposes that the programme be named against every effect estimate in the assessed-outcome table.

The document should state what a reader ought to do

The draft on Semaglutide is a substantial document and the respondent has confined this submission to one matter.

The draft assesses evidence and stops. The respondent, a practising clinician, states that a reader arriving at the document with a decision to make is left to convert an assessment into an action without help, and proposes that each document close with a recommendation.

The respondent argues that other evidence bodies issue recommendations and that declining to do so transfers the difficult part of the work to the reader.

The respondent has read submission 001 above and makes this submission independently of it.

The pharmacokinetic section does not connect half-life to the dosing schedule

This submission concerns Semaglutide and makes one point.

The draft reports a half-life and, separately, a dosing interval. The respondent, a clinical pharmacologist, states that the relationship between the two is what determines accumulation and time to steady state, and that the monograph leaves the reader to derive it.

The respondent proposes that time to steady state be stated explicitly, with the assumption from which it was derived.

Quantitative claims are reproduced without the method that produced them

The respondent submits on the draft monograph for Semaglutide. The observation arises from teaching the material rather than from prescribing it.

Several figures in the draft are quoted from sources that determined them by different methods. A figure obtained by one determination and a figure obtained by another are not comparable, and the draft places them in the same sentence without distinguishing them.

The respondent, an analytical chemist, proposes that every quantitative claim carry the method that produced it at the point of use rather than in the reference.

The monograph should state what the compound costs

The draft on Semaglutide was read in full. The respondent notes at the outset that this class has an unusually deep randomised evidence base, and that a monograph on it is fairly judged against a higher standard than one on a compound with none.

The respondent states that a reader deciding whether to pursue treatment needs to know what it costs, and that omitting price makes the assessment less useful than it could be.

The respondent proposes that a price range be recorded for each compound with the source and date.

This submission is made by a respondent with a different professional interest in the outcome from the one behind submission 002.

References should carry a persistent identifier for every cited source

Having reviewed the draft on Semaglutide, the respondent makes a single submission, on the view that one point put clearly is more use to the secretariat than six put together.

Several references in the draft carry a journal, a year and a volume but no persistent identifier. The respondent states that retrieval of such a reference is materially slower and that identifiers should be supplied throughout.

The respondent asks in the alternative that where an identifier exists but is not carried, the omission be explained rather than left as a gap the reader must interpret.

Submission 002 concerns the same document. The respondent’s point is a different one.

The monograph should not describe how the compound is supplied outside a regulated route

The respondent works on cardiometabolic outcomes and read the draft on Semaglutide with that literature in view.

The respondent states that describing presentations observed in unregulated supply risks being read as a guide to obtaining them, and asks that the material be removed.

The respondent accepts that the information is accurate and objects to its presence rather than to its content.

Mechanistic claims for a peptide fragment are carried without evidence that the fragment acts as described

This is a submission on Semaglutide.

The respondent states that the draft repeats a mechanistic account originating in supply documentation rather than in the primary literature, and that the account attributes activity to a fragment on the basis of the activity of the parent molecule.

The respondent proposes that any mechanistic claim be traceable to a primary source and removed where it is not.

Every contributing trial shares one sponsor and the monograph does not say so

This submission addresses the draft monograph on Semaglutide. The respondent went through the document twice, once as a specialist and once as a reader arriving without the background.

The respondent, who has published a systematic review of this literature, states that all of the contributing trials for the principal outcome were conducted by a single sponsor, and that this is a property of the evidence base rather than a criticism of any individual trial.

The respondent proposes that sponsor concentration be recorded as a characteristic of the evidence base in the certainty assessment rather than as a note in the discussion.

The analytical section is longer than the clinical assessment it accompanies

This submission concerns Semaglutide and a convention used across the Institute’s output.

The respondent states that the analytical section occupies more of the monograph than the assessment of clinical effect, and that the proportions imply the Institute considers the analytical question the more important one.

The respondent proposes that the analytical material be moved to the standards series and referenced rather than reproduced.

This point is adjacent to the one made in submission 003 and the respondent puts it in a form the secretariat can act on.

Registered trials that never reported are absent from the monograph

This submission concerns the draft on Semaglutide. The respondent assesses incretin-class evidence for a national body and comments in a personal capacity.

The respondent states that the trial list appears to be drawn from published reports, and that registered trials which completed without a report are therefore invisible. The proportion of a programme that never reported is itself a finding about the evidence base.

The respondent proposes that every registered trial of the compound be listed, with its reporting status, whether or not a report exists.

Open-label extension data are presented alongside randomised data without distinction

The respondent submits on Semaglutide, on a matter that is not specific to this draft but is visible in it.

Long-term figures in the clinical section come from open-label extensions in which every participant received the active compound and those who did not tolerate it had already withdrawn. They are printed in the same table as randomised comparisons and in the same typeface.

The respondent proposes that extension data be presented in a separate table, or at minimum in a separately labelled block, and that the surviving-population problem be stated once where it arises.